最新动态
联系我们

上海私家侦探援助中心|上海私人侦探婚外遇调查-上海纳德私人调查

手机:

微信:

公司宗旨:

您浏览的位置:主页 > 新闻动态 >

以岭药业新产品:五专利中药纳入国家基药目录 有利于长远发展

发布于:2018-12-20 14:30

10月26日晚,以岭药业发布公告称,公司专利产品通心络胶囊、连花清瘟胶囊(颗粒)、芪苈强心胶囊、津力达颗粒和参松养心胶囊进入《国家基本药物目录》(2018年版)。
 
On the evening of October 26, Yiling Pharmaceutical Company announced that its patented products Tongxinluo Capsule, Lianhua Qingwen Capsule (Granule), Qilu Qiangxin Capsule, Jinlida Granule and Shensong Yangxin Capsule entered the National Essential Drugs Catalogue (2018 edition).
 
 
 
据了解,国家基本药物目录所纳入的都是拥有诊疗规范、临床诊疗指南和专家共识依据,疗效确切、价格合理、临床应用价值高的药物。按照规定,各级医疗机构必须全面配备基本药物,并在心脑血管病、糖尿病等慢性病管理中优先使用基本药物,以确保药物治疗的安全、有效。
 
It is understood that the National Essential Medicines Catalogue includes drugs with definite curative effect, reasonable price and high clinical application value, all of which have the criteria of diagnosis and treatment, clinical diagnosis and treatment guidelines and expert consensus basis. According to the regulations, medical institutions at all levels must be fully equipped with essential drugs, and give priority to the use of essential drugs in the management of chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes and so on, in order to ensure the safety and effectiveness of drug treatment.
 
 
 
 
 
上述五个专利中药作为公司主力产品,2017年上述产品收入合计为347,139.97万元,占2017年公司主营业务收入406,948.22万元的85.30%。2018年1-6月上述产品收入合计为229,276.97万元,占2018年1-6月公司主营业务收入269,707.20万元的85.01%。
 
The above five patented Chinese medicines are the main products of the company. In 2017, the total revenue of the above-mentioned products was 347,139.97 million yuan, accounting for 85.30% of the company's main business income of 406,948.22 million yuan in 2017. From January to June 2018, the total revenue of the above products was 229,276.97 million yuan, accounting for 85.01% of the company's main business income of 269,707.20 million yuan from January to June 2018.
 
 
 
以岭药业相关人士表示,络病理论的创新有力地促进了创新药物研发,形成一批专利新药,如通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊、津力达颗粒等10多个国家专利中药,另有处于临床研究阶段的中药十余个,临床前在研品种二十余个,形成处于不同研发阶段的系列专利药物集群,涵盖心脑血管病、糖尿病、呼吸系统、肿瘤等重大疾病领域。凭借卓越的临床疗效,创新中药连续斩获了4项国家科技进步二等奖,1项国家技术发明二等奖和多项省部级奖项,使得通络创新中药在我国医药界形成了特有的品牌,形成了巨大的市场。此次五个专业中药进入《国家基本药物目录》(2018年版),预计将对上述产品市场占有率快速提升以及公司长远发展产生积极作用。
 
Relevant personages in Ling Pharmaceutical Industry indicated that the innovation of collateral pathology theory has effectively promoted the research and development of innovative drugs and formed a batch of patent new drugs, such as Tongxinluo Capsule, Shensong Yangxin Capsule, Qilan Qiangxin Capsule, Lianhua Qingwen Capsule, Jinlida Granule and more than 10 patented Chinese medicines in the clinical research stage. More than 20 varieties were studied before the clinic and formed offices. A series of patent drug clusters covering cardio-cerebrovascular disease, diabetes mellitus, respiratory system, cancer and other major diseases at different stages of research and development. With excellent clinical efficacy, innovative Chinese medicines have won four second prizes for national scientific and technological progress, one second prize for national technological invention and many provincial and ministerial awards, which have made Tongluo innovative Chinese medicines a unique brand and a huge market in China's pharmaceutical industry. The entry of five professional Chinese medicines into the National Essential Medicines Catalogue (2018 edition) is expected to have a positive effect on the rapid increase of market share of the above products and the long-term development of the company.

下一篇:定制化手机或将成三星未来方向
上一篇:纸箱回收机拼不过垃圾桶?混入垃圾回收效率大打折扣